Price
$9.47+2.16%Social Signal Score
Analyst Ratings
10 analysts52-week range
- Last close
- $9.47
- Off 52w high
- -53.5%
- 200-day average
- $13.07
- vs 200-day
- -27.6%
Revenue
$124.39M+4134.20%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Adam S. Grossman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 644
- Beta
- 0.77
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 7.37
Financials
Revenue
$124.39M+4134.2%Net Income
$37.82MEBITDA
$57.28MFree Cash Flow
$27.28MEPS (diluted)
$0.16Shares Outstanding (diluted)
230.34M+1687.4%Operating Expenses
$32.75MCash & Debt
$136.02MReturn of Capital
$25.05MRevenue by Segment (annual)
$427.10MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $510.17M | $146.93M | $0.62 |
| 2024 | $426.45M | $197.67M | $0.85 |
| 2023 | $258.21M | $-28.24M | $-0.13 |
| 2022 | $154.08M | $-65.90M | $-0.43 |
| 2021 | $80.94M | $-71.65M | $-0.61 |
| 2020 | $42.22M | $-75.75M | $-1.02 |
| 2019 | $29.35M | $-48.28M | $-1.05 |
| 2018 | $16.99M | $-65.74M | $-1.45 |
| 2017 | $22.76M | $-43.76M | $-1.91 |
| 2016 | $10.66M | $-19.52M | $-1.61 |
| 2015 | $7.18M | $-17.97M | $-1.73 |
| 2014 | $5.92M | $-16.81M | $-1.81 |
| 2013 | $3.07M | $-15.53M | $-2.38 |
| 2012 | $1.12M | $-7.30M | $-1.39 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.91
- Implied price
- $26.27
- Return from $9.72
- 22.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $13.06 — today's price is already 25.6% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 25 | 29 | 33 | 37 |
|---|---|---|---|---|---|
| -2.0% | 3.8% | 7.5% | 10.7% | 13.6% | 16.2% |
| 3.0% | 9.1% | 13.0% | 16.4% | 19.4% | 22.2% |
| 8.0% | 14.4% | 18.4% | 22.0% | 25.2% | 28.1% |
| 13.0% | 19.7% | 23.9% | 27.7% | 31.0% | 34.0% |
| 18.0% | 25.0% | 29.4% | 33.3% | 36.8% | 40.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-67.03%Social Signal Score
Mentions (16)
- Newszacks.com·6d ago·Neutral
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.
View source ↗ - Newszacks.com·11d ago·Neutral
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.
View source ↗ - Newszacks.com·11d ago·Neutral
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
View source ↗ - Newszacks.com·17d ago·Positive
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.
View source ↗ - Newsnewsfilecorp.com·22d ago·Neutral
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA) Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite …
View source ↗ - Newszacks.com·24d ago·Negative
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.
View source ↗ - Newszacks.com·25d ago·Neutral
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know Adma Biologics (ADMA) closed at $9.36 in the latest trading session, marking a -1.01% move from the prior day.
View source ↗ - Newszacks.com·27d ago·Neutral
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
View source ↗ - Newsprnewswire.com·28d ago·Neutral
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company").
View source ↗ - Newszacks.com·31d ago·Neutral
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound? Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsprnewswire.com·35d ago·Neutral
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) PHILADELPHIA, Aug. 31, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand…
View source ↗ - Newsnewsfilecorp.com·42d ago·Neutral
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA) Philadelphia, Pennsylvania--(Newsfile Corp. - August 24, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite dec…
View source ↗ - Newsprnewswire.com·49d ago·Neutral
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) PHILADELPHIA, Aug. 17, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand…
View source ↗ - Newszacks.com·53d ago·Neutral
Can Asceniv Help ADMA Stock Combat IG Market Challenges? Asceniv drives ADMA's growth with rising adoption and real-world evidence, while competitive pressure weighs on Bivigam sales.
View source ↗ - Newsseekingalpha.com·54d ago·Neutral
ADMA Biologics: The Earnings Reset Still Leaves More Upside ADMA Biologics faces a lower earnings base after some challenging times, but ASCENIV remains its key growth driver. Despite reduced long-term targets, Q2 saw ASCENIV revenue up 24%, gross margin at 69%, and improved receivable collection, supporting valuation confidence. My Buy thesis rests on continued ASCENIV growth from the reset base, not a reversal of prior shocks or restored guidance.
View source ↗ - Newsnewsfilecorp.com·55d ago·Neutral
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA) Philadelphia, Pennsylvania--(Newsfile Corp. - August 12, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite dec
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.19 per share
Typical surprise -1.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.16 vs $0.16miss
- Wed, May 6$0.19 vs $0.19miss
- Wed, Feb 25$0.20 vs $0.18beat
- Wed, Nov 5$0.16 vs $0.16beat
- Wed, Aug 6$0.15 vs $0.14beat
- Wed, May 7$0.14 vs $0.16miss
Estimates and results for ADMA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ADMA officers and directors.
- Bought
- $468k
- Sold
- $8.3m
5 trades
21 trades
- Grossman Jerrold Bbought
- Grossman Jerrold Bbought
- Grossman Jerrold Bbought
- Grossman Adam Ssold
- Grossman Adam Ssold
- Kestenberg-messina Kaitlin M.sold
- Elms Stevebought
- Elms Stevebought
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ADMA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.